156 related articles for article (PubMed ID: 35485207)
1. A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis.
Eguchi A; Iwasa M; Yamada M; Tamai Y; Shigefuku R; Hasegawa H; Hirokawa Y; Hayashi A; Okuno K; Matsushita Y; Nakatsuka T; Enooku K; Sakaguchi K; Kobayashi Y; Yamaguchi T; Watanabe M; Takei Y; Nakagawa H
Hepatol Commun; 2022 Aug; 6(8):1987-1999. PubMed ID: 35485207
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease.
Kim YS; Jung ES; Hur W; Bae SH; Choi JY; Song MJ; Kim CW; Jo SH; Lee CD; Lee YS; Choi SW; Yang JM; Jang JW; Kim SG; Jung SW; Kim HK; Chae HB; Yoon SK
Clin Mol Hepatol; 2013 Jun; 19(2):120-30. PubMed ID: 23837136
[TBL] [Abstract][Full Text] [Related]
3. The prognostic potential of fragmented CK18 serum levels in HCC patients reflecting disease progression and overall hepatocyte damage.
Eguchi A; Iwasa M; Tamai Y; Yamada M; Okuno K; Shigefuku R; Yoshikawa K; Tempaku M; Sakaguchi K; Tanaka H; Sugimoto K; Kobayashi Y; Yamaguchi T; Nakagawa H
Front Oncol; 2022; 12():993705. PubMed ID: 36081568
[TBL] [Abstract][Full Text] [Related]
4. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
5. Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease.
Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
Int J Clin Exp Med; 2014; 7(11):4191-8. PubMed ID: 25550930
[TBL] [Abstract][Full Text] [Related]
6. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
[TBL] [Abstract][Full Text] [Related]
7. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.
Tsutsui M; Tanaka N; Kawakubo M; Sheena Y; Horiuchi A; Komatsu M; Nagaya T; Joshita S; Umemura T; Ichijo T; Matsumoto A; Yoshizawa K; Aoyama T; Tanaka E; Sano K
J Clin Gastroenterol; 2010 Jul; 44(6):440-7. PubMed ID: 20104187
[TBL] [Abstract][Full Text] [Related]
8. [Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis].
Yang M; Liu Y; Zhou G; Guo X; Zou S; Liu S; Jiang L; Liu Y; Zhu L; Guo C; Zhao J
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):96-101. PubMed ID: 26983475
[TBL] [Abstract][Full Text] [Related]
9. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
[TBL] [Abstract][Full Text] [Related]
10. Development of a highly sensitive chemiluminescent enzyme immunoassay for fragmented cytokeratin 18 using new antibodies.
Yamada M; Eguchi A; Okuno K; Sakaguchi K; Yamaguchi T
Sci Rep; 2021 Sep; 11(1):18187. PubMed ID: 34521905
[TBL] [Abstract][Full Text] [Related]
11. Classification of patients with non-alcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with liver histology and other fibrosis markers.
Mizuno M; Shima T; Oya H; Mitsumoto Y; Mizuno C; Isoda S; Kuramoto M; Taniguchi M; Noda M; Sakai K; Koyama N; Okanoue T
Hepatol Res; 2017 Feb; 47(2):216-225. PubMed ID: 26997642
[TBL] [Abstract][Full Text] [Related]
12. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
[TBL] [Abstract][Full Text] [Related]
13. Transaminase Concentrations Cannot Separate Non-Alcoholic Fatty Liver and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients Irrespective of Histological Algorithm.
Lemmer P; Selbach N; Baars T; Porsch-Özcürümez M; Heider D; Canbay A; Sowa JP
Dig Dis; 2022; 40(5):644-653. PubMed ID: 34469884
[TBL] [Abstract][Full Text] [Related]
14. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers.
Chan WK; Sthaneshwar P; Nik Mustapha NR; Mahadeva S
PLoS One; 2014; 9(9):e105903. PubMed ID: 25184298
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis.
Cao W; Zhao C; Shen C; Wang Y
PLoS One; 2013; 8(12):e82092. PubMed ID: 24324749
[TBL] [Abstract][Full Text] [Related]
16. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
17. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
18. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
[TBL] [Abstract][Full Text] [Related]
19. The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease.
Nakamura A; Yamamoto K; Takeda R; Yamada R; Kubo A; Morikawa K; Ando S; Shimazaki T; Izumi T; Umemura M; Kitagataya T; Shigesawa T; Suzuki K; Kimura M; Nakai M; Sho T; Suda G; Natsuizaka M; Ogawa K; Ohnishi S; Sugiyama T; Takeda H; Sakamoto N
Hepatol Res; 2022 Jun; 52(6):508-521. PubMed ID: 35129841
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study.
Zhang Y; He H; Zeng YP; Yang LD; Jia D; An ZM; Jia WG
Lipids Health Dis; 2020 Jun; 19(1):134. PubMed ID: 32527258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
